Evotec begins construction on Toulouse biologics manufacturing facility

By The Science Advisory Board staff writers

April 20, 2021 -- Evotec will soon break ground on its first commercial biologics manufacturing facility in Europe at its Campus Curie in Toulouse, France.

Construction is expected to commence in the second half of this year on the facility, which will support the development and manufacturing of therapeutic antibodies for the treatment of infectious diseases, such as COVID-19, upon its planned completion in 2023, Evotec said.

The company's initial biologics manufacturing facility is nearing completion in Redmond, WA, and is scheduled to be fully operational in the second half of 2021.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.